|
Market Closed -
Nasdaq
21:00:00 01/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 154.27 USD | +9.93% |
|
-2.87% | +423.13% |
| 09-01 | GSK Moves mRNA Flu Vaccine Candidate to Late-Stage Trial | DJ |
| 09-01 | GSK to advance mRNA flu vaccine to late-stage trial | RE |
| Market Cap | 61.59B 53.13B 49.97B 45.53B 85.61B 5,845B 86.08B 591B 230B 2,973B 231B 226B 9,859B | P/E 2026 * |
-18.1x | P/E 2027 * | -31.4x |
|---|---|---|---|---|---|
| Enterprise Value | 57.94B 49.98B 47.01B 42.83B 80.54B 5,499B 80.98B 556B 216B 2,797B 218B 213B 9,275B | EV / Sales 2026 * |
27.6x | EV / Sales 2027 * | 24.3x |
| Free-Float |
92.68% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Moderna, Inc.
| 1 day | +9.93% | ||
| 1 week | -2.87% | ||
| Current month | +9.93% | ||
| 1 month | +181.41% | ||
| 3 months | +234.93% | ||
| 6 months | +187.98% | ||
| Current year | +423.13% |
| 1 week | 133.33 |  | 154.7 |
| 1 month | 52.66 | | 176.66 |
| Current year | 29.81 | | 176.66 |
| 1 year | 22.28 | | 176.66 |
| 3 years | 22.28 | | 176.66 |
| 5 years | 22.28 | | 464.85 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 05/09/2022 |
Stephen Hoge
PSD | President | 50 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 28/02/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 10/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/08/26 | Exercice | Chief Executive Officer | 504,938 | 0.1273% | ||
| 15/07/26 | Exercice | Chairperson | 160,008 | 0.0403% | ||
| 08/07/26 | Free | Director | 14,766 | 0.0037% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.93% | -2.87% | +540.39% | +37.06% | 61.59B | |
| +3.10% | -1.17% | +41.87% | -0.94% | 82.26B | |
| +0.50% | +0.39% | -16.92% | -35.51% | 59.05B | |
| +0.13% | -4.10% | -0.74% | +34.87% | 51.23B | |
| +1.49% | -2.50% | +9.69% | +163.06% | 48.3B | |
| -0.28% | -2.14% | +63.39% | -19.14% | 31.92B | |
| +1.45% | -3.63% | +47.75% | +93.24% | 25.34B | |
| -0.79% | -8.20% | -4.27% | +192.17% | 22.56B | |
| +1.69% | -2.60% | +61.63% | +116.78% | 16.56B | |
| -2.11% | -1.47% | -14.00% | +794.40% | 15.28B | |
| Average | +1.51% | -1.49% | +72.88% | +137.60% | 41.41B | |
| Weighted average by Cap. | +2.36% | -1.59% | +96.84% | +72.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.81B 1.7B 1.55B 2.91B 199B 2.93B 20.11B 7.83B 101B 7.87B 7.7B 336B | 2.44B 2.11B 1.98B 1.81B 3.4B 232B 3.41B 23.44B 9.12B 118B 9.17B 8.97B 391B |
| Net income | -3.31B -2.86B -2.69B -2.45B -4.6B -314B -4.63B -31.78B -12.37B -160B -12.44B -12.17B -530B | -1.94B -1.67B -1.58B -1.43B -2.7B -184B -2.71B -18.62B -7.25B -93.71B -7.29B -7.13B -311B |
| Net Debt | -3.65B -3.15B -2.96B -2.7B -5.07B -346B -5.1B -35B -13.62B -176B -13.7B -13.4B -584B | -2.19B -1.89B -1.78B -1.62B -3.05B -208B -3.07B -21.04B -8.19B -106B -8.24B -8.06B -351B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/09/26 | US$154.27 | +9.93% | 25,831,743 |
| 31/08/26 | US$140.34 | +1.70% | 18,570,704 |
| 28/08/26 | US$137.99 | -3.35% | 25,820,563 |
| 27/08/26 | US$142.77 | -4.60% | 24,993,236 |
| 26/08/26 | US$149.66 | -5.77% | 22,009,462 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
